Product How it works Pricing Blog FAQ About Contact
Crescent Biopharma

Crescent Biopharma (NASDAQ: CBIO) revenue

Crescent Biopharma reported revenue of $10.8m for fiscal 2025; in fiscal 2023 it was $0.0m. Since fiscal 2016 its revenue has grown by 58,516.2%, an average growth of 103.0% a year.

Fiscal 2025 is the highest of the 6 fiscal years on record for Crescent Biopharma. The biggest drop was in fiscal 2022, −93.5%.

Revenue, in millions of US dollars0.0201610.220201.220210.120220.0202310.82025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$10.8m—−$152.6m−1,407.5%
2023$0.0m−86.7%−$39.3m−392,752.9%
2022$0.1m−93.5%−$47.4m−63,204.4%
2021$1.2m−88.6%−$63.4m−5,470.7%
2020$10.2m—−$51.5m−506.8%
2016$0.0m—−$31.9m−172,505.3%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Crescent Biopharma revenue compared with its sector

By revenue for its latest fiscal year, Crescent Biopharma ranks 366th of the 422 US health care companies with a page on Celsmar.

RankCompanyRevenueRevenue growth
364thPrelude Therapeutics$12.1m73.4%
365thCaribou Biosciences$11.2m11.7%
366thCrescent Biopharma$10.8m—
367thJanux Therapeutics$10.0m−5.6%
368thZenas BioPharma$10.0m100.0%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Crescent Biopharma

How much revenue did Crescent Biopharma make in fiscal 2025?
Crescent Biopharma reported revenue of $10.8m for fiscal 2025, compared with $0.0m in fiscal 2023.
How much has the revenue of Crescent Biopharma grown?
Between fiscal 2016 and fiscal 2025 it went from $0.0m to $10.8m: 58,516.2% more, an average growth of 103.0% a year.
What was the best year for revenue at Crescent Biopharma?
Of its last 6 fiscal years, fiscal 2025, with $10.8m.
Where does Crescent Biopharma rank in its sector by revenue?
It ranks 366th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Crescent Biopharma come from?
From the annual report (Form 10-K) that Crescent Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Crescent Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2023 · 2022 · 2021 · 2020 · 2016. More on Crescent Biopharma: the Crescent Biopharma page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.